AIM: To elucidate risk factors contributing to the development of hepatocellular carcinoma (HCC) among patients with sustained viral response (SVR) after interferon (IFN) treatment and to examine whether HCV-RNA still remained in the liver of SVR patients who developed HCC. METHODS: Two-hundred and sixty-six patients, who achieved SVR, were enrolled in this study. We retrospectively reviewed clinical, viral and histological features of the patients, and examined whether the development of HCC depends on several clinical variables using Kaplan-Meier Method. RT-PCR was used to seek HCV-RNA in 3 out of 7 patients in whom liver tissue was available for molecular analysis. RESULTS: Among the enrolled 266 patients with SVR, HCC developed in 7 patients (7/266; 2.6%). We failed to detect HCV-RNA both in cancer and non-cancerous liver tissue in all three patients. The cumulative incidence for HCC was significantly different depending on hepatic fibrosis (F3-4) (P = 0.0028), hepatic steatosis (Grade 2-3) (P = 0.0002) and age (> or = 55) (P = 0.021) at the pre-interferon treatment. CONCLUSION: The current study demonstrated that age, hepatic fibrosis, and hepatic steatosis at pre-interferon treatment might be risk factors for developing HCC after SVR.
AIM: To elucidate risk factors contributing to the development of hepatocellular carcinoma (HCC) among patients with sustained viral response (SVR) after interferon (IFN) treatment and to examine whether HCV-RNA still remained in the liver of SVR patients who developed HCC. METHODS: Two-hundred and sixty-six patients, who achieved SVR, were enrolled in this study. We retrospectively reviewed clinical, viral and histological features of the patients, and examined whether the development of HCC depends on several clinical variables using Kaplan-Meier Method. RT-PCR was used to seek HCV-RNA in 3 out of 7 patients in whom liver tissue was available for molecular analysis. RESULTS: Among the enrolled 266 patients with SVR, HCC developed in 7 patients (7/266; 2.6%). We failed to detect HCV-RNA both in cancer and non-cancerous liver tissue in all three patients. The cumulative incidence for HCC was significantly different depending on hepatic fibrosis (F3-4) (P = 0.0028), hepatic steatosis (Grade 2-3) (P = 0.0002) and age (> or = 55) (P = 0.021) at the pre-interferon treatment. CONCLUSION: The current study demonstrated that age, hepatic fibrosis, and hepatic steatosis at pre-interferon treatment might be risk factors for developing HCC after SVR.
Authors: N Hirashima; M Mizokami; E Orito; T Koide; I Itazu; K Kumada; K Sakakibara; H Kano; J Y Lau Journal: J Gastroenterol Hepatol Date: 1996-10 Impact factor: 4.029
Authors: Vlad Ratziu; Luminita Bonyhay; Vincent Di Martino; Frederic Charlotte; Lucas Cavallaro; Marie-Hélène Sayegh-Tainturier; Philippe Giral; André Grimaldi; Pierre Opolon; Thierry Poynard Journal: Hepatology Date: 2002-06 Impact factor: 17.425
Authors: Sheetal Trivedi; Satyapramod Murthy; Himanshu Sharma; Alex S Hartlage; Arvind Kumar; Sashi V Gadi; Peter Simmonds; Lokendra V Chauhan; Troels K H Scheel; Eva Billerbeck; Peter D Burbelo; Charles M Rice; W Ian Lipkin; Kurt Vandegrift; John M Cullen; Amit Kapoor Journal: Hepatology Date: 2018-05-21 Impact factor: 17.425
Authors: Lindsay Matthews; David E Kleiner; Cheryl Chairez; Maryellen McManus; Mary Jane Nettles; Kira Zemanick; Caryn Gee Morse; Debra Benator; Joseph A Kovacs; Colleen Hadigan Journal: AIDS Res Hum Retroviruses Date: 2015-08-24 Impact factor: 2.205